Renovo, plc.
From Wikipedia, the free encyclopedia
| Renovo, plc. | |
|---|---|
| Type | Public (LSE: RNVO) |
| Founded | October 2000 |
| Headquarters |  Manchester, UK |
| Key people | Mark Ferguson (CEO) Sharon O'Kane |
| Industry | Biotechnology |
| Products | 4 in clinical development |
| Website | www.renovo.com |
Renovo, plc. (LSE: RNVO) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research[1], and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"[2] in 2009.
The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes[3].
[edit] Products
Currently the company doesn't have a marketed product, though its pipeline includes one drug in phase III clinical development, three drugs in phase II clinical development, and numerous pre-clinical candidates.
| Drug | Phase | Action |
|---|---|---|
| Juvista | Phase II Clinical trial | Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring |
| Zesteem | Phase III Clinical trial | Accelerates the re-epithelialization of the skin following wounding |
| Prevascar | Phase II Clinical trial | Injected to the wound margins around the time of surgery causes a reduction of scarring |
| Juvidex | Phase II Clinical trial | Accelerates the re-epithelialization in split thickness skin graft donor sites |
[edit] References
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
